| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Cytochrome P450 3A4 |
|---|
| Ligand | BDBM50379681 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_812035 (CHEMBL2013461) |
|---|
| IC50 | >50000±n/a nM |
|---|
| Citation |  Davies, DJ; Crowe, M; Lucas, N; Quinn, J; Miller, DD; Pritchard, S; Grose, D; Bettini, E; Calcinaghi, N; Virginio, C; Abberley, L; Goldsmith, P; Michel, AD; Chessell, IP; Kew, JN; Miller, ND; Gunthorpe, MJ A novel series of benzimidazole NR2B-selective NMDA receptor antagonists. Bioorg Med Chem Lett22:2620-3 (2012) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Cytochrome P450 3A4 |
|---|
| Name: | Cytochrome P450 3A4 |
|---|
| Synonyms: | Albendazole monooxygenase | Albendazole sulfoxidase | CP3A4_HUMAN | CYP3A3 | CYP3A4 | CYPIIIA3 | CYPIIIA4 | Cytochrome P450 3A3 | Cytochrome P450 3A4 (CYP3A4) | Cytochrome P450 HLp | Nifedipine oxidase | Quinine 3-monooxygenase | Taurochenodeoxycholate 6-alpha-hydroxylase |
|---|
| Type: | Enzyme |
|---|
| Mol. Mass.: | 57349.57 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | n/a |
|---|
| Residue: | 503 |
|---|
| Sequence: | MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA
|
|
|
|---|
| BDBM50379681 |
|---|
| n/a |
|---|
| Name | BDBM50379681 |
|---|
| Synonyms: | CHEMBL2010880 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C19H21N3 |
|---|
| Mol. Mass. | 291.3901 |
|---|
| SMILES | C(N1CCCCC1)c1cccc2nc([nH]c12)-c1ccccc1 |
|---|
| Structure | 
|
|---|
Search and Browse
